Patent ID: 11918689
Assignee: TRIS PHARMA, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 12:
13. The extended hour release oral clonidine aqueous suspension according to claim 1, wherein the cation exchange resin of (A) and/or (B) comprises a sulfonated copolymer of styrene and divinylbenzene and a mobile (exchangeable) cation is sodium with a total cation exchange capacity of about 5 meq/g, and further comprises an average particle size of 10% to 25% in the range of 0.075 mm and no more than 1% being greater than 0.150 mm in size, and has about 9.4% to 11.5% sodium, a potassium exchange capacity of 110 to 135 mg/g, a heavy metals content of less than 10 ppm.